Hamlet Biopharma, a company innovating the treatment of cancer and infections, today announced the successful granting of new patents in Japan and India and a further patent allowance in Japan. The continued strengthening of Hamlet BioPharma’s intellectual property portfolio reaffirms its position at the forefront of technological innovation.

The new patents and allowances cover breakthroughs in the HAMLET family of drug candidates, which effectively kill cancer cells and growing tumor tissue with high precision, as well as the company’s technology relating to the treatment of bacterial infections, including cystitis.

With these latest additions, Hamlet BioPharma now holds about 150 active patents and over 30 pending patent applications across numerous countries, showcasing a robust innovation strategy designed to fuel long-term growth, protect proprietary technologies, and drive value for partners and customers alike.

The company plans to integrate these patented technologies with Phase III clinical trial activities and ongoing product development.

For further information, please contact

Catharina Svanborg, Chairman of the Board, Hamlet BioPharma AB, +46 709 42 65 49,

catharina.svanborg@hamletpharma.com

Jakob Testad, CEO, Hamlet BioPharma AB, +46 708 48 42 10,

jakob.testad@hamletbiopharma.com

www.hamletbiopharma.com